• Login
    View Item 
    •   UTMB Health SHARED Home
    • Electronic Theses and Dissertations
    • Published ETD Collection
    • View Item
    •   UTMB Health SHARED Home
    • Electronic Theses and Dissertations
    • Published ETD Collection
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Folate Receptor-Targeted Transplacental Delivery of Digoxin for the Treatment of Fetal Arrhythmia

    Thumbnail
    View/Open
    ALBEKAIRI-DISSERTATIONDOCTORAL-2015.pdf (3.733Mb)
    Author
    Albekairi, Norah A
    0000-0001-6802-0647
    Metadata
    Show full item record
    Abstract
    Fetal tachyarrhythmias is one of the leading causes of fetal hydrops and, ultimately, fetal demise. This condition is typically treated with transplacental digoxin by maternal administration. However, maternal digoxin administration is associated with nausea, vomiting, heart block and sinus bradycardia. Additionally, placental efflux mechanisms limit the transfer of digoxin to the fetus. When transplacental digoxin therapy fails, direct fetal injection of digoxin is performed. This can result in fetal injury, infection, and in severe cases, fetal demise. The purpose of this project is to develop a novel therapeutic strategy using nanoparticles targeting the placenta to increase digoxin delivery to the fetus. Biocompatible digoxin-loaded polymeric nanoparticles were prepared and their physicochemical and drug release characteristics were determined. Using BeWo (choriocarcinoma) cells as an in vitro transplacental transport model, we were able to show that these nanoparticles increase permeability of digoxin across the placenta by evading placental efflux. Conjugation of folic acid to the surface of these nanoparticles increased the transplacental transfer of digoxin due to folate receptor-mediated endocytosis. Folate receptors are highly expressed in the placental trophoblast throughout pregnancy due to the importance of folic acid in fetal and placental development. We believe that this novel treatment strategy may increase the transfer of digoxin to the fetus and ultimately reduce maternal side effects and the need for direct fetal digoxin administration. This should result in better maternal and fetal outcomes in cases of fetal tachyarrhythmia.
    URI
    https://hdl.handle.net/2152.3/11142
    Collections
    • Published ETD Collection

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV
     

     

    Browse

    All of UTMB Health SHAREDCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy DepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Department

    My Account

    Login

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    TDL
    Theme by 
    Atmire NV